At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.